Resultats de la cerca - JF Forbes

  • Mostrar 1 - 5 resultats de 5
Refinar resultats
  1. 1
    Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer--96-Month Follow-up of the Randomized IBIS-I Trial

    Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer--96-Month Follow-up of the Randomized IBIS-I Trial per Jack Cuzick, JF Forbes, Ivana Šestak, Simon Cawthorn, H. Hamed, K Holli, Anthony Howell

    Publicat 2007
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS‐II DCIS)

    Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS‐II DCIS) per Ilona Juraskova, Phyllis Butow, Angeles Lopez, M Seccombe, Alan S. Coates, F Boyle, Nicole McCarthy, Linda Reaby, JF Forbes

    Publicat 2008
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Multicentre randomised controlled trial of the clinical and cost-effectiveness of a bypass-surgery-first versus a balloon-angioplasty-first revascularisation strategy for severe limb ischaemia due to infrainguinal disease. The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial

    Multicentre randomised controlled trial of the clinical and cost-effectiveness of a bypass-surgery-first versus a balloon-angioplasty-first revascularisation strategy for severe li... per AW Bradbury, D.J. Adam, Jocelyn Bell, JF Forbes, F. G. R. Fowkes, Iain Gillespie, Gillian Raab, CV Ruckley

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

    Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial per Manuela Rabaglio, Zijie Sun, Karen N. Price, Monica Castiglione‐Gertsch, Hanne Hawle, Beat Thürlimann, Henning T. Mouridsen, Mario Campone, JF Forbes, Robert Paridaens, Marco Colleoni, Tadeusz Pieńkowski, Jean‐Marie Nogaret, István Láng, Ian Smith, Richard D. Gelber, Aron Goldhirsch, Alan S. Coates

    Publicat 2009
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial

    Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial per Giuseppe Viale, MM Regan, Patrizia DellʼOrto, Mauro G. Mastropasqua, Eugenio Maiorano, Blake B. Rasmussen, Gaëtan MacGrogan, JF Forbes, Robert Paridaens, Marco Colleoni, István Láng, Beat Thürlimann, Henning T. Mouridsen, L. Mauriac, RD Gelber, K.N. Price, Aron Goldhirsch, B A Gusterson, Coates As

    Publicat 2011
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: